You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)治療突變中國胃腸道間質瘤藥物具抗腫瘤活性
基石藥業-B(02616.HK)公布,於《The Oncologist》雜誌線上發表泰吉華(阿伐替尼片)NAVIGATOR中國橋接研究結果。結果顯示,泰吉華對攜帶PDGFRA D842V突變的中國胃腸道間質瘤(GIST)患者展示出優越和持久的抗腫瘤活性,對四線及以上的中國GIST患者也展示良好的抗腫瘤活性。 泰吉華是一款強效、高選擇性、口服針對KIT和PDGFRA突變的激(酉每)抑制劑,由基石藥業合作夥伴Blueprint Medicines(BPMC.US)開發。基石藥業與Blueprint Medicines達成獨家合作和授權協議,獲得泰吉華在大中華地區(包括中國、香港、澳門和台灣)的獨家開發和商業化授權。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account